ARTV
Artiva Biotherapeutics, Inc.NASDAQHealthcare$6.74-0.15%ClosedMarket Cap: $166.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.50
P/S
0.00
EV/EBITDA
-1.75
DCF Value
$0.64
FCF Yield
-47.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-60.2%
ROA
-64.0%
ROIC
-74.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-22.7M | $-20.8M | $-0.85 | — |
| FY 2025 | $0.00 | -Infinity% | $-90.6M | $-83.9M | $-3.43 | — |
| Q3 2025 | $0.00 | -Infinity% | $-22.9M | $-21.5M | $-0.88 | — |
| Q2 2025 | $0.00 | NaN% | $-22.8M | $-21.3M | $-0.87 | — |
| Q1 2025 | $0.00 | NaN% | $-22.2M | $-20.3M | $-0.83 | — |
| Q4 2024 | $0.00 | NaN% | $-18.3M | $-9.2M | $-0.82 | — |
| FY 2024 | $251.0K | 100.0% | $-67.3M | $-58.5M | $-5.20 | — |
| Q3 2024 | $0.00 | NaN% | $-18.3M | $-17.5M | $-0.92 | — |
| Q2 2024 | $0.00 | NaN% | $-16.2M | $-17.8M | $-0.62 | — |
| Q1 2024 | $251.0K | 100.0% | $-14.5M | $-14.0M | $-0.79 | — |
| Q4 2023 | $2.4M | 100.0% | $-12.0M | $-12.0M | $-0.54 | — |
| FY 2023 | $33.5M | 100.0% | $-30.7M | $-27.7M | $-1.19 | — |